Danish drugmaker Novo Nordisk said today that it will cut the prices of several of its insulin products in the United States by up to 75%.It is another major international drug company that slashed the price of insulin by Eli Lilly and Lilly earlier in the month. After going under external pressure has reduced the price of insulin in the United States.diabetesCost of medical drugs.
Novo Nordisk is one of the largest suppliers of insulin in the United States and around the world. “The Wall Street Journal” (The Wall Street Journal) reported that Novo Nordisk said today that the price of its insulin product Novolog will be reduced by 75% in the United States from January next year, and the other two insulins, Novolin and Levemir, will also be reduced by 65%.
In addition, Novo Nordisk also intends to reduce the price of its non-branded insulin products in the United States to match the lower prices of related brand products.
“Novo Nordisk’s ongoing commitment to making our insulin affordable for people with diabetes is a responsibility we take seriously,” said Steve Albers, Senior Vice President, Novo Nordisk.
many haveInsuranceAmericans may not see a similar reduction in the cost of insulin they pay because they pay a fixed monthly copay. However, people who don’t have insurance or take high-deductible plans can enjoy a sharp drop in drug prices after the price reduction.
Eli Lilly (Eli Lilly), a large US pharmaceutical company, announced on the first of this month that it would reduce the price of its most popular prescription insulin products by 70% from the fourth quarter of this year; Extended monthly victim deductible cap set at $35 applies.
The day Eli Lilly announced the price cut, President Joe Biden issued a statement praising it, noting that “Americans are sometimes forced to pay more than $300 for a drug that cost less than $10. That’s just not right.” He also called on other manufacturers to follow suit to address rising drug prices.
Eli Lilly, Novo Nordisk and LawsinopharmThe world’s top insulin vendors such as Sanofi significantly increased the prices of their own insulin products in the 2010s. But these drug makers have said that the price hike has not given them any major advantage as they have to pay for the U.S. The Pharmaceutical Benefits Administrator will also have to pay a substantial portion of the kickbacks.
US (tags to translate) Insurance (T) Diabetes (T) Sinopharm
